Cormorant Capital

Cormorant Capital

Cormorant Capital

Xconomy

Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia

Xconomy

BridgeBio's Pipeline Expansion Continues as Portfolio's Milestones Approach

Technical.ly Philly

University City biotech firm Cabaletta Bio Inc. goes public in $74.8M IPO

PE HUB

VC-backed Cabaletta Bio begins trading on NASDAQ

Xconomy

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

PE HUB

Satsuma Pharmaceuticals goes public

Xconomy

BridgeBio Upsizes IPO to $348M, Topping Adaptive’s Wall Street Debut

MedCity News

BridgeBio files for $225M initial public offering

$299,200,000 Venture capital
PE HUB

BridgeBio Pharma racks up $299.2 mln

$50,000,000 Venture capital (Series B)
MedCity News , FinSMEs

Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies

Xconomy

BridgeBio Picks Up Novartis Cancer Drug, Launches New Biotech Startup

Health Science
Xconomy

BridgeBio Bags $135M For “Hub and Spoke” Rare Disease Drug R&D

Health Funding
$12,000,000 Venture capital (Series A)
PE Hub

Satsuma Pharmaceuticals takes in $12 mln Series A